Rheumatologie 2009

Was ist neu ?

• Kardiovaskuläres Risiko bei rheumatoider Arthritis: Hauptfaktoren Krankheitsaktivität und Nikotinabusus.

• Biologika: Hemmung von IL-6 genauso effektiv wie Hemmung von TNF.

• Kortikosteroide: Abendliche Einnahme einer zeitverzögerten Galenik erreicht endogenes Steroidtief am frühen Morgen.

• „Small Molecules”: Klinische Wirksamkeit weiterhin nicht erreicht.

• Kollagenosen und Vaskulitiden: Konventionelle Immunsuppressiva gewinnen gegenüber Cyclophosphamid an Bedeutung.

• Bildgebung: Gelenkultraschall und Nagelfalzkapillaroskopie diagnostischer und Facharztstandard.

Literatur

• 1 Alten R E, Zerbini C, Jeka S. et al . Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy.  Ann Rheum Dis. , epub ahead of print
• 2 Backhaus M. Ultrasound and structural changes in inflammatory arthritis: synovitis and tenosynovitis.  Ann N Y Acad Sci. 2009;  1154 139-151
• 3 Bertsias G, Ioannidis J P, Boletis J. et al . EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.  Ann Rheum Dis. 2008;  67 195-205
• 4 Braun J, Kästner P, Flaxenberg P. et al . Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.  Arthritis Rheum. 2008;  58 73-81
• 5 Buttgereit F, Doering G, Schaeffler A. et al . Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.  Lancet. 2008;  371 205-214
• 6 Emery P, Keystone E, Tony H P. et al . IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.  Ann Rheum Dis. 2008;  67 1516-1523
• 7 Gottlieb A, Menter A, Mendelsohn A. et al . Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.  Lancet. 2009;  373 633-640
• 8 Ingegnoli F, Boracchi P, Gualtierotti R. et al . Prognostic model based on nailfold capillaroscopy for identifying Raynaud’s phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (prognostic index for nailfold capillaroscopic examination).  Arthritis Rheum. 2008;  58 2174-2182
• 9 Kain R, Exner M, Brandes R. et al . Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis.  Nat Med. 2008;  14 1088-1096
• 10 Kay J, Matteson E L, Dasgupta B. et al . Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.  Arthritis Rheum. 2008;  58 964-975
• 11 Keystone E, Heijde D, Mason D. et al . Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.  Arthritis Rheum. 2008;  58 3319-3329
• 12 Klareskog L, Catrina A I, Paget S. Rheumatoid Arthritis.  Lancet. 2009;  373 659-672
• 13 Kowal-Bielecka O, Landewé R, Avouac J. et al . EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).  Ann Rheum Dis. 2009;  68 620-628
• 14 Leombruno J P, Einarson T R, Keystone E C. The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analyses of serious adverse events.  Ann Rheum Dis. 2008;  epub ahead of print
• 15 Mukhtyar C, Guillevin L, Cid M C. et al . EULAR recommendations for the management of primary small and medium vessel vasculitis.  Ann Rheum Dis. 2009;  68 310-317
• 16 Mukhtyar C, Guillevin L, Cid M C. et al . EULAR recommendations for the management of large vessel vasculitis.  Ann Rheum Dis. 2009;  68 318-323
• 17 Schumacher H R, Becker M A, Wortmann R L. et al . Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.  Arthritis Rheum. 2008;  59 1540-1548
• 18 Smolen J S, Beaulieu A, Rubbert-Roth A. et al . Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.  Lancet. 2008;  371 987-997
• 19 van Staa T P, Smeeth L, Persson I, Parkinson J, Leufkens H G. What is the harm-benefit ratio of Cox-2 inhibitors?.  Int J Epidemiol. 2008;  37 405-413